This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • A mini-review for cancer immunotherapy: molecular ...
Journal

A mini-review for cancer immunotherapy: molecular understanding of pd-1/pd-l1 pathway & translational blockade of immune checkpoints.

Read time: 1 mins
Published:18th Jul 2016
Author: Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, et al.
Availability: Free full text
Ref.:Int J Mol Sci. 2016 Jul 18;17(7). pii: E1151.
DOI:10.3390/ijms17071151.

Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.

Read abstract on library site

Access full article